ClinicalTrials.gg
Not yet recruitingNCT07940946AstroIDHUpdated Nov 17, 2026

A Phase 3, Multicenter Study of Vorasidenib in Combination With Temozolomide (TMZ) in Participants With IDH1- or IDH2 Mutant High-grade Astrocytoma.

A Phase 3 interventional study of Vorasidenib and Placebo in IDH-mutant High-grade Astrocytoma, sponsored by Institut de Recherches Internationales Servier. Not yet recruiting. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Primary conditionAstrocytomaRegistry: GliomaReclassifiedWhy we changed it
Registry
Glioma — the first condition term the registry derived for this study.
ClinicalTrials.gg
Astrocytoma
Why
  1. The study's listed conditions name Astrocytoma, a narrower term within Glioma.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Institut de Recherches Internationales Servier · Phase 3, Interventional, and Treatment

Updated Nov 17, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
550
Allocation
Randomized
Ages
12 Years and older
Sex
All
01

Study summary

The objective of this study is to establish the efficacy and safety of vorasidenib in combination with TMZ, compared to placebo with TMZ, in participants ages 12 and older with newly diagnosed, isocitrate dehydrogenase (IDH) mutant high-grade astrocytoma. The study will include a screening period, a treatment period consisting of continuous 28-day cycles of treatment, a safety follow-up, progression free survival follow-up, and survival follow-ups every 3 months until study completion. During Cycles 1 through 12 of the treatment period participants will receive TMZ along with either vorasidenib or placebo and then from Cycle 13 through the end of treatment participants will only receive vorasidenib or placebo. At study visits participants may undergo blood tests, magnetic resonance imaging (MRI), electrocardiogram (ECG), vital sign checks, questionnaires, and physical exams.

02

Conditions studied

  • IDH-mutant High-grade Astrocytoma

Browse trials for

Keywords

  • IDH-mutant glioma
  • IDH mutation
  • high grade glioma
  • vorasidenib
  • S095032
  • pediatric
  • high grade astrocytoma
03

In context

Astrocytoma Reclassified

688 studies on the registry are indexed under Astrocytoma; 80 are open to participants now.

This study's planned enrollment of 550 is above the median of 31 across 531 interventional studies indexed under Astrocytoma.

Browse Astrocytoma studies →

Lead sponsor

Institut de Recherches Internationales Servier is the lead sponsor of 68 studies on the registry; 5 are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 9 (50%) have results posted.

Compared within Astrocytoma, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Glioma. The counts are of registry records indexed under each term, refreshed daily. How we classify →

04

Who can participate

Ages eligible
12 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Be ≥ 12 years of age with a weight at screening ≥ 40 kg.
  • Have a confirmed diagnosis of de novo high-grade astrocytoma, IDH mutant, CNS WHO grade 3 or 4 astrocytoma (per the WHO 2021 criteria). Those who meet the CNS WHO grade 4 designation via cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) homozygous deletion are eligible. Absence of 1p19q codeletion (i.e., non codeleted, or intact) and/or documented loss of nuclear ATRX chromatin remodeler (ATRX) expression or ATRX mutation must be confirmed by local testing. CDKN2A/B deletion status must be confirmed by local testing for all participants.
  • Have documented centrally confirmed IDH mutation status during the pre-screening period.
  • Have expected survival of ≥ 3 months.
  • Have undergone surgery for glioma (partial/subtotal resection, gross-total resection, ) followed by standard of care RT with or without concurrent TMZ as per local practice (for participants with CNS WHO grade 3 astrocytoma) or RT-TMZ (for participants with CNS WHO grade 4 astrocytoma) as their only anticancer treatment before enrollment and at an RT dose of ≥ 59.4 Gy (proton radiotherapy not allowed). Randomization must occur no more than 6 weeks after the last dose of RT.
  • Have adequate renal, bone marrow, and hepatic function

Exclusion criteria

Exclusion Criteria:

  • Have received prior therapy with any anticancer therapy for the disease aside from RT or RT-TMZ, including IDH inhibitors, IDH-directed vaccine, or bevacizumab.
  • Have had progressive disease (PD) during or after completion of standard of care RT or RT TMZ and before randomization.
  • Have had Grade 4 hematologic toxicity (excluding lymphopenia) that did not recover within 7 days during concurrent RT-TMZ.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
550 participants (estimated)

Study arms

  • Experimental
    Vorasidenib and Temozolomide (TMZ)

    Drug: Vorasidenib · Drug: Temozolomide (TMZ)

  • Placebo comparator
    Placebo and Temozolomide (TMZ)

    Drug: Placebo · Drug: Temozolomide (TMZ)

Interventions

  • DrugVorasidenib

    Tablets to be taken by mouth, once daily, until study participation stops

  • DrugPlacebo

    Tablets to be taken by mouth, once daily, until study participation stops

  • DrugTemozolomide (TMZ)

    Tablets or capsules (depending on the form available in the participants country) to be taken by mouth, once daily on days 1-5 of each cycle, from Cycle 1 through Cycle 12. Cycles are 28-days each.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    The time from date of randomization to date of the first occurrence of progressive disease (PD) assessed by the Blinded Independent Review Committee (BIRC) per Response Assessment in Neuro-oncology (RANO) 2.0 or death from any cause, whichever occurs earlier.

    Time frame: Through study completion, approximately 7.5 years

Secondary outcomes

  1. Overall Survival (OS)

    The time from date of randomization to date of death due to any cause.

    Time frame: Through study completion, approximately 7.5 years

  2. PFS

    As assessed by the investigator per RANO 2.0.

    Time frame: Through study completion, approximately 7.5 years

  3. Clinical Benefit Rate (CBR) as assessed by the investigator

    Defined as a best overall response of complete response (CR), partial response (PR), or stable disease (SD)

    Time frame: Through study completion, approximately 7.5 years

  4. Clinical Benefit Rate (CBR) as assessed by the BIRC per RANO 2.0

    Defined as a best overall response of complete response (CR), partial response (PR), or stable disease (SD)

    Time frame: Through study completion, approximately 7.5 years

  5. Objective Response Rate (ORR) as assessed by the investigator

    Defined as a best overall response of CR or PR

    Time frame: Through study completion, approximately 7.5 years

  6. Objective Response Rate (ORR) as assessed by the BIRC per RANO 2.0

    Defined as a best overall response of CR or PR

    Time frame: Through study completion, approximately 7.5 years

  7. Duration of Response (DOR)

    Defined for participants with objective response (OR) as the time from the first documentation of OR to the first documentation of PD or death due to any cause, whichever occurs earlier.

    Time frame: Through study completion, approximately 7.5 years

  8. Time to Response as assessed by the investigator

    Defined as the time from the date of randomization to the date of first documented CR or PR for responders

    Time frame: Through study completion, approximately 7.5 years

  9. Time to Response as assessed by the BIRC per RANO 2.0

    Defined as the time from the date of randomization to the date of first documented CR or PR for responders

    Time frame: Through study completion, approximately 7.5 years

  10. Time to Next Intervention (TTNI)

    Defined as the time from the date of randomization to the initiation of first subsequent anticancer therapy or death due to any cause, whichever occurs earlier.

    Time frame: Through study completion, approximately 7.5 years

  11. Progression-Free Survival 2 (PFS2)

    Defined as the time from the date of randomization to first progression by investigator after initiation of subsequent anticancer therapy following initial progression as assessed by the BIRC or death due to any cause, whichever occurs earlier.

    Time frame: Through study completion, approximately 7.5 years

  12. Tumor Growth Rate (TGR)

    As assessed by volume and defined as the percentage change in tumor volume every 6 months as assessed per BIRC.

    Time frame: Through study completion, approximately 7.5 years

  13. Number of adverse events (AEs), serious AEs (SAEs), and AEs of special interest (AESIs)

    Time frame: Through study completion, approximately 7.5 years

  14. Severity of AEs, SAEs, and AESIs

    Time frame: Through study completion, approximately 7.5 years

  15. Health-related quality of life (HRQoL) as assessed by the EQ-5D-5L questionnaire

    The EuroQol 5 Dimensions 5 Levels (EQ-5D-5L) scores range from 0 to 100 with a higher number indicating better health.

    Time frame: Through end of treatment, up to 7.5 years

  16. HRQoL as assessed by the EORTC QLQ C30 questionnaire

    The European Organization for Research and Treatment of Cancer quality of life core questionnaire (EORTC QLQ C30) QoL scores range from 0 to 100 with a higher number indicating better QoL.

    Time frame: Through end of treatment, up to 7.5 years

  17. Symptom burden as assessed by the MDASI-BT questionnaire

    The MD Anderson Symptom Inventory Brain Tumor (MDASI-BT) scores range from 0 to 10 with a higher number indicating more severe symptoms.

    Time frame: Through end of treatment, up to 7.5 years

  18. Symptom burden as assessed by the EORTC QLQ-BN20 questionnaire

    The European Organization for Research and Treatment of Cancer quality of life brain tumor module (EORTC QLQ-BN20) scores range from 0 to 100 with a higher number indicating more severe symptoms.

    Time frame: Through end of treatment, up to 7.5 years

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified scientific and medical researchers can request access to anonymized patient-level and study-level clinical trial data. Access can be requested for all interventional clinical studies: used for Marketing Authorization (MA) of medicines and new indications approved after 1 January 2014 in the European Economic Area (EEA) or the United States (US). where Servier is the Marketing Authorization Holder (MAH). The date of the first MA of the new medicine (or the new indication) in one of the EEA Member States will be considered for this scope. In addition, access can be requested for all interventional clinical studies in patients: sponsored by Servier with a first patient enrolled as of 1 January 2004 onwards for New Chemical Entity or New Biological Entity (new pharmaceutical form excluded) for which development has been terminated before any Marketing authorization (MA) approval.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: After Marketing Authorization in EEA or US if the study is used for the approval.

Access criteria: Researchers should register on Servier Data Portal and fill in the research proposal form. This form in four parts should be fully documented. The Research Proposal Form will not be reviewed until all mandatory fields are completed.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2027; primary completion for Nov 2034, 92 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2026
First posted
Nov 17, 2026
StartEst.
Mar 1, 2027
Primary completionEst.
Nov 1, 2034
CompletionEst.
Nov 1, 2034
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07940946
Lead sponsor
Institut de Recherches Internationales Servier
Responsible party
Sponsor
First posted
Nov 17, 2026
Start date
Mar 1, 2027 (estimated)
Primary completion
Nov 1, 2034 (estimated)
Completion
Nov 1, 2034 (estimated)
Last update
Nov 17, 2026

Study contacts

Institut de Recherches Internationales Servier (I.R.I.S.)
Contact
scientificinformation@servier.com
+33 1 55 72 60 00

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion